In Q4 2024, Cormorant Asset Management held 44 positions worth $1.8B. They initiated 6 new positions and exited 50. Their largest holding was MLTX ($460.0M). Portfolio value grew +1.8% versus the prior quarter.
Frequently asked questions
What stocks did Cormorant Asset Management own in Q4 2024?
Cormorant Asset Management held 44 biotech stocks in their 13F portfolio in Q4 2024. Their top positions include MLTX, PRAX, JANX, ACLX, EWTX. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Cormorant Asset Management's portfolio worth in Q4 2024?
Cormorant Asset Management's tracked biotech portfolio was worth $1.8B across 44 positions, with total assets under management of approximately $4B. Portfolio values are based on 13F filings with the SEC.
What did Cormorant Asset Management buy in Q4 2024?
Cormorant Asset Management initiated 6 new positions in Q4 2024, including DRUG, OKUR, SEPN, SPRY, KALA and 1 more. They also increased 8 existing positions.
What did Cormorant Asset Management sell in Q4 2024?
Cormorant Asset Management fully exited 50 positions in Q4 2024, including PSTX, PRME, RXDX, PYXS, TNGX and 45 more. They also trimmed 10 existing positions.
Is Cormorant Asset Management a biotech fund?
Healthcare-focused crossover fund that invests from late-stage private through public markets. Known for concentrated, high-conviction positions in clinical and commercial-stage biotech companies with strong scientific differentiation.
Want AI analysis, insider signals, and catalyst overlays for Cormorant Asset Management?
View latest Cormorant Asset Managementportfolio →